Organon Stock Jumps on Sun Pharma Deal: Key Risks Ahead Organon stock is rated Hold as Sun Pharma confirmed an all-cash $14 offer. Shares surged, but weakening earnings make it a deal-and-timing risk, not fundamentals, and upside is limited near today’s price. 2026년 04월 28일 English
